论文部分内容阅读
目的探讨关节腔注射复方倍他米松联合依那西普治疗类风湿关节炎(RA)的临床疗效。方法选择2010年3月至2011年10月在我院就诊治疗的124例类风湿关节炎患者,随机分为治疗组(关节腔注射复方倍他米松联合依那西普针治疗)和对照组(关节腔单用复方倍他米松治疗),各组均为62例,观察比较两组患者的关节压痛值数、血沉(ESR)、C-反应蛋白(C-reactive protein,CRP)以及类风湿因子(rheumatoid factor,RF)的改善情况,并分析比较两组患者治疗的总有效率。结果治疗组关节压痛缓解值数明显优于对照组(P<0.05),并且治疗组ESR、CRP、RF改善情况也显著优于对照组(P<0.05);两组患者总的有效率比较,治疗组优于对照组(P<0.05))。两组患者均未发生严重不良反应。结论关节腔注射复方倍他米松联合依那西普治疗类风湿关节炎临床疗效显著,可改善各项临床疗效指标,不良反应较单用复方倍他米松组少,值得临床广泛应用。
Objective To investigate the clinical efficacy of combination intra-articular injection of compound betamethasone and etanercept in the treatment of rheumatoid arthritis (RA). Methods A total of 124 patients with rheumatoid arthritis who were treated in our hospital from March 2010 to October 2011 were randomly divided into treatment group (intra-articular injection of compound betamethasone and etanercept) and control group ( Articular cavity alone compound betamethasone treatment), each group was 62 cases, the two groups were observed in patients with joint tenderness value, ESR, C-reactive protein (C-reactive protein, CRF) and rheumatoid factor (rheumatoid factor, RF) to improve the situation, and analysis of two groups of patients treated with the total efficiency. Results Compared with the control group, the treatment group had significantly better relief of joint tenderness (P <0.05), and the improvements of ESR, CRP and RF in the treatment group were also significantly better than those in the control group (P <0.05) The treatment group was better than the control group (P <0.05)). No serious adverse reactions occurred in both groups. Conclusions The clinical effect of compound injection of compound betamethasone and etanercept on rheumatoid arthritis is significant and the clinical curative indexes can be improved. The adverse reaction is less than that of compound betamethasone alone, which is worthy of clinical application.